Table 1.
Patients with PVE
| Authors | Citation | Nature of study | No | Period of study | Diagnoses | Morbidity of PVE | Time to discharge after PVE | Mean duration to surgery (days) | Resectability rate | Operative mortality | Liver failure | Operative morbidity | Increase of liver volume | Failure of hypertrophy | Post op stay (days) | Disease progression |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azoulay [3] | Ann Surg. 2000 Apr;231(4):480–6. | R | 30 | 1990–1998 | CRC | 3 % | NM | 63+/−45 | 63 % | 3 % | NIL | 16 % | 14–71 %; median =42 % | NIL | NM | 33 % |
| Nimura [6] | Ann Surg. 2006 Mar;243(3):364–72 | P | 240 | 1991–2005 | CC 150 GB Ca 90 | 0.83 % | NM | 14–21 | 80.40 % | 8.80 % | 2.07 % | NM | 7–19 % | NIL | NM | 19.58 % |
| Covey [17] | Ann Surg 2008 Mar;247 (3) :451–5 | P | 100 | 1999–2004 | CRC | 1 % | NM | 41–76 (20–255) | 65.50 % | 2 % | NM | 31 % | 22+/−3 % | 10 % | 8 (4–23) | NM |
| Wakabayashi [24] | Surgery 2002; Jan; 131 (1);26–33 | R | 43 | 1991–2000 | HCC 25, CC 8, OM 10 | NIL | NM | 21–26 | 100 % | NIL | NM | 13.90 % | 32.93 % | NM | NM | NM |
| di Stefano [25] | Radiology 2005;234; 625-30 | R, MC | 188 | 1990–2001 | HCC 32, CC 15, OM 137, BENIGN 4 | 12.80 % | NM | 33–39 | 86 % | NM | NM | NM | 41–62 % | 1.59 % | NM | 6.38 % |
| Farges O, Belghiti [26] | Ann Surg. 2003 Feb;237(2):208–17 | P, RT | 27 | 1998–2000 | CRC10, HCC 14, CC 1, NET 2 | NIL | NM | 49+/−13 | 100 % | 3.57 % | 3.57 % | 25 % | 33+/−10 % | 14 % | 13+/−4 | 6.45 % |
| Cotroneo [27] | Eur J Surg Oncol. 2009 Jan;35(1):71–8 | R | 31 | NM | CRC13, HCC 7, CC 9, GB Ca 2 | 6.45 % | NM | NM | 77.41 % | NIL | NM | NM | 44.2 % non cirrhotic, 32.1 %: cirrhoitic | 6.45 % | NM | 16.12 % |
| Immamura [28] | Hepatology. 1999 Apr;29(4):1099–105. | R | 84 | 1990–1998 | HCC 5, CC 49, GB Ca 22, OM 7, Hemangioma 1 | 2.56 % | NM | 17 | 79 | 3 % | 1.50 % | NM | 30 % −median | NIL | NM | 21.42 % |
| de Baere [29] | Hepatology 1996 Dec;24(6):1386–91. | P | 31 | 1989–1995 | CRC 22, HCC 1, CC 1, OM 7 | 3.22 % | NM | 32 | 77 % | 8.30 % | NIL | 8.30 % | 79+/−50 % | 3.22 % | NM | 12.90 % |
| Jaeck [30] | Surgery. 2008 Apr;143(4):476–82. | R | 146 | 1997–2006 | CRC 106, HCC 10, CC 19, GB Ca 06, NET 5 | 10 % | 4+/−1 days | NM | 79 % | NIL | 4 % | 43 % | 47.7 %+/−31.9 % | 5.51 % | NM | 13.10 % |
| Makuuchi [31] | Hepatogastroenterology. 1991 Aug;38(4):329–36. | P | 54 | NM | CRC 8, HCC 31, CC 12, OM 3 | NIL | NM | 21 | 85 % | 2.17 % | NM | 15.21 % | NM | NM | NM | NM |
| Dong Dae Seo [32] | Ann Surg Oncol. 2007 Dec;14(12):3501–9 | R | 32 | 1999–2001 | HCC | NIL | NM | median = 21 | 58 % | NIL | 12.50 % | 18.75 % | 34 % | 15.60 % | median = 20 | NIL |
| L. Mueller [33] | Ann Surg Oncol. 2008 Jul;15(7):1908–17. | R | 40 | 1995–2004 | CRC | NIL | NM | 50.5 −combined data from PVE/PVL | 55.00 % | 2.30 % | NM | NM | 50.10 % | 10 % | 12 | 35.00 % |
| Vauthey [34] | Br J Surg. 2007 Nov;94(11):1386–94 | R | 112 | 1995–2006 | CRC 50, HCC 24, CC 14, GB Ca 6, OM 18 | 8.90 % | NM | NM | 69.60 % | 3 % | 15.38 % | 44 % | 9.85 % | 4.46 % | 8 days (5–53) | 19.64 % |
| Capussotti [35] | Arch Surg 2008 Oct;143(10):978–82; discussion 982 | R | 31 | 2000–2006 | CRC | NIL | 3 | NM | 77.41 | 3.50 % | NM | 16.66 % | 53.40 % | NM | NM | NM |
| Pamecha [36] | Ann Surg Oncol (2009) 16:1202–1207 | R | 36 | 1999–2005 | CRC | 6 % | NM | 42 | 61 % | 4.50 % | 4.54 % | 36 % | 37 % median | NIL | median = 13 | 33 % |
| Thierry de Baere [37] | Ann Surg Oncol (2010) 17:2081–2089 | R | 107 | 1987–2005 | CRC 79, HCC 10, OM 11, NET 7 | NIL | NM | 34 | 88 % | 3.73 % | 9.34 % | 23.36 % | 69 % | NIL | NM | 12 % |
| D. A. Wicherts [38] | British Journal of Surgery 2010; 97: 240–250 | R | 99 | 1990–2006 | CRC | NM | NM | 56.7 | 68 % | 1.50 % | 19.40 % | 49 % | NM | 3 % | 18 | 27.27 % |
| Ratti [39] | Updates Surg (2010) 62:153–159 | R | 62 | 2006–2009 | CRC 32, HCC 7, CC 10, GB Ca 13 | NIL | NM | 35 +/−10 | 90.32 % | nil | 3.20 % | 32 % | 50.3%mean | 3.22 % | 11+/−4 | 6.45 % |
| Hyunkyung Yoo[40] | Eur Radiol (2009) 19: 1054–1061 | R | 39 | 2006–2007 | HCC 16, CC 19, OM 2, Misc 2 | 4.87 % | NM | NM | 78.04 % | NM | NM | NM | 22.74 % mean | NM | NM | 17.04 % |
R retrospective, P prospective, NM not mentioned, CRC colorectal liver metastasis, HCC hepato-cellular cancer, CC cholangiocellular cancer, GBCa gall bladder cancer, NET nuero-endocrine tumour, OM other metastatic lesions